Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Australia Plans New Approval Pathways To Foster Earlier Access To Novel Drugs

Executive Summary

The Australian government has come up with a set of proposals for reforming the drug and medical device regulatory framework, which include speeding up access to innovative drugs through expedited and provisional approval mechanisms and greater use of assessments by overseas regulators. The changes will be phased in over a period of about three years and may include some recovery of costs from industry.

You may also be interested in...

Australia To Make Access To Unauthorized Products Faster And Less Bothersome

New proposals by Australia’s Therapeutic Goods Administration include developing a list of unauthorized drugs that could be made available to patients faster and more easily. A decision to include a product on the list would not be appealable, the TGA says.

No Delays Expected As Australian Bill On Faster Drug Approvals Goes To Parliament

The Australian parliament has held its first reading of a bill that will implement a number of new measures in the pharmaceutical area, including two new expedited drug approval pathways and a risk-based approach to variations.

English A Must In Australian Proposals On Using Overseas Assessments

Australia believes that using overseas assessment reports will help the Therapeutic Goods Administration cut the time it takes to review drug applications by up to three months. Meanwhile, a work-sharing scheme could make it easier for applicants to enter multiple international markets.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts